Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Oxford have found that an individual’s immune system – and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.

The study by the University of Oxford’s Department of Oncology and Kennedy Institute, supported by the NIHR Oxford Biomedical Research Centre (BRC), suggests that pancreatic cancer can be categorised in terms of a person's own immune system. The research also involved colleagues from the universities of Cambridge, Birmingham, Leeds and Maastricht.

The paper, Immuno‐phenotypes of Pancreatic Ductal Adenocarcinoma: Meta‐analysis of transcriptional subtypes, is published in the International Journal of Cancer.

Pancreatic cancer is an aggressive cancer and has limited treatment options. In the early stages of the disease, the tumour often causes few symptoms, which can make it difficult to diagnose. After diagnosis, only 5% of patients survive for five years. Even after an operation in the earliest stages of the disease, only 20% of patients are alive after five years.

The study conducted a meta‐analysis of 353 pancreatic cancer patients from four different studies to derive a classification based on immunological parameters. It found that if pancreatic cancer patients had higher levels of T-cells – a type of white blood cell that plays a key role in a body’s immune response – in their cancer, they would live longer after an operation. In contrast, those whose tumour had higher levels of neutrophil cells - a component of the innate immune system – fared worst after surgery.

People who had neither neutrophils nor T cells in their cancer would on average live for a couple of years after an operation before dying from their cancer.

“This is a significant step forward in our understanding of this recalcitrant disease. Prognosis is generally very poor, and we need to find new ways to treat it,” said Dr Shivan Sivakumar, Clinical Lecturer in Oncology at the University of Oxford, who led the study.

“Although our approach will need to be validated in larger studies, it does suggest that we are now able to stratify pancreatic cancer based on how a person's own immune system reacts to the cancer.

“Existing immune treatments that work well against skin cancer and lung cancer do not work in pancreatic cancer. However, we can now start studying other types of immune therapy, based on the immune cell ‘signatures’ present in a patient’s pancreatic cancer.”

Dr Sivakumar continued: “In Oxford, we are now profiling the immune system in the tumour in great depth, so we can identify every cell present. This would help us decide how and in whom immune-therapy might work best. This will tell us how future clinical trials should be designed.”

 

Similar stories

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.